期刊文献+

动脉化疗栓塞治疗晚期卵巢癌

Intra-arterial Chemo-embolization in the Treatment of Advanced Ovarian Cancer
原文传递
导出
摘要 目的探讨经动脉化疗栓塞治疗晚期卵巢癌的疗效。资料与方法对48例晚期卵巢癌患者行髂内动脉、卵巢动脉化疗栓塞,其中Ⅲ期26例、Ⅳ期22例,灌注药物剂量分别为:顺铂(DDP)50mg/m2或卡铂400~600mg、丝裂霉素(MMC)6~10mg。栓塞剂选用明胶海绵。在介入术前3h静脉注射5-氟尿嘧啶(5-FU)1000~1250mg。结果采用单纯介入治疗者总有效率69.2%(9/13),完全缓解(CR)4例,部分缓解(PR)5例,稳定(SD)3例,进展(PD)1例,患者2年生存率46.2%(6/13)。采用介入+手术治疗者总有效率91.4%(32/35),CR21例,PR11例,SD3例,患者2年生存率71.4%(25/35)。无严重并发症发生。结论经导管动脉化疗栓塞治疗晚期卵巢癌疗效肯定,为综合治疗晚期卵巢癌增加了新的治疗手段,并为无法手术者提供了二期手术机会。 Objective To study the effect of intra-arterial chemo-embolization in the treatment of advanced ovarian cancer. Materials and Methods The interventional therapy was performed in 48 patietns with advanced ovarian cancer. 26 cases were in stage Ⅲ,22 cases were in stage Ⅳ. The drug dose was DDP 50mg/m2 or CBP 400-600mg,MMC 6-10mg. the embolic agent was gelfoam. 5-FU 1000-1250mg was given through intervenous drip three hours before the interventional therapy. Results Among the recurrent cancer (4CR,5PR,3SD,1PD),the overall responserate (RR) was 69.2% (9/13) ,2-year survival rate were 38.5%. Among the primar? cancer (21CR,11PR,3SD) ,the overall responserate (RR) was 91.4% (32/35) ,2-year survival rate was 71.4%. Nonhematopoietic toxicities were mild and tolerable. Conelusion Transcathter superselective chemo-embolization has appositive effect on advanced ovarian cancer. It has provided a new method for the comprehensive treatment of advanced ovarian cancer, and it wll give operable chance for the patient wbo were not suitable primarily with surgery.
出处 《临床放射学杂志》 CSCD 北大核心 2009年第12期1673-1675,共3页 Journal of Clinical Radiology
关键词 卵巢癌 介入性 化疗 栓塞 Ovarian cancer Interventional Chemotherapy Embolization
  • 相关文献

参考文献6

二级参考文献29

  • 1Tiemey J. Neoadjuvant chemotherapy for locally advanced eervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomized trials[J]. Eur J Cancer, 2003, 39:2470-2486.
  • 2Tattersall MH,Lorvidhaya V, Vootiprux V, et al. Randomized trial of epirubiein and eisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association [J]. J Clin Oncol, 1995, 13:444-451.
  • 3Panici PB- Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer prognostic factors for response and survival[ J]. Cancer, 1991,67:372-379.
  • 4Napolitano C, Imoerano F, Mossa B, et al. The role of neoadjuvant chemotherapy for squamous cell cervical cancer (ⅠB-ⅢB ) : a Long-term randomized trial[ J ]. Eur J Gynaec Oncol, 2002,14: 51-59.
  • 5Sardi JE ,Sananes CE ,Giaroli AA,et al. Neoadjuvant chemotherapy in cervical carcinoma stage ⅡB : a randomized controlled trial [J]. Int J Gynecol Cancer, 1998,8:441-450.
  • 6Park DC. Phase Ⅱ trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer[ J]. Gynecol Oncol, 2004,92:59-63.
  • 7Duenas-Gonzales A, Lopez-Graniel Concomitant chemoradlation versus C, Gonzalez-Enciso A, et al. neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase Ⅱ studies [ J ]. Ann Oncol, 2002,13 : 1212-1219.
  • 8Eddy GL. Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage b bulky cervical cancer:a Gynecologic Ontology Group pilot study[J]. Gynecol Oncol, 1995,57:412-416.
  • 9Griffhhs CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma[J]. Natl Cancer Inst Monogr, 1975, 42 : 101-104.
  • 10Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis[ J]. Gynecol Oncol, 2006,103 : 1070-1076.

共引文献152

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部